- NCIt
- C7480
Loading cancer entity…
Loading cancer entity…
Clinical trials
744 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02217956 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma(CHIPASTIN) | completed | Phase 1 | 30 | Gustave Roussy, Cancer Campus, Grand ParisOTHER |
| 1 |
| Aug 13, 2026 |
| clinicaltrials |
| NCT03586661 | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02759588 | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | completed | Phase 1 / Phase 2 | 46 | Genelux CorporationINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | completed | Phase 1 | 86 | Shattuck Labs, Inc.INDUSTRY | 4 | Dec 23, 2025 | clinicaltrials |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | completed | Phase 1 | 64 | TransgeneINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | completed | Phase 1 | 136 | Sutro Biopharma, Inc.INDUSTRY | 2 | Aug 20, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | completed | Phase 1 | 65 | University of PennsylvaniaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT01220154 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | completed | Phase 1 | 9 | David O'MalleyOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04406623 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | Shattuck Labs, Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | completed | Phase 1 | 18 | ImunonINDUSTRY | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03539406 | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients(INTRO) | completed | Phase 1 | 11 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02344095 | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer(POPOPO) | completed | Phase 1 | 12 | Seoul National University HospitalOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT03126812 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 140 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 10, 2024 | clinicaltrials |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 / Phase 2 | 88 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT00066729 | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 9 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00803569 | Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | completed | Phase 1 | 13 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00562640 | Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04630769 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | completed | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 1 / Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT00616941 | Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 28 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02788708 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | completed | Phase 1 | 26 | Floor BackesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03056833 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 1 | 35 | Ronald BuckanovichOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT01673217 | Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02324439 | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | completed | Phase 1 | 15 | Southern Illinois UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials